---
schema_version: "secwatch.filing_event.v1"
accession: "0001140361-22-040018"
form_type: "8-K"
ticker: "IRD"
cik: "0001228627"
company_name: "Opus Genetics, Inc."
filed_at: "2022-11-04T23:59:59+00:00"
generated_at: "2026-06-22T06:35:51.337573+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Ocuphire Q3 net loss $4.5M; Nyxol NDA on track for Q4 2022

## Summary
- Cash and equivalents of $13.9M as of Sept 30, 2022; runway into Q4 2023.
- Net loss of $4.5M for Q3 2022 ($0.22 per share); R&D expenses $2.8M.
- NDA submission for Nyxol (reversal of mydriasis) planned in Q4 2022.
- Topline data from ZETA-1 Phase 2b trial of APX3330 expected early 2023.
- U.S. patent for Nyxol extended into 2039; new KOLs appointed to advisory board.

## SEC filing metadata
- accession: 0001140361-22-040018
- form_type: 8-K
- ticker: IRD
- cik: 0001228627
- company_name: Opus Genetics, Inc.
- filed_at: 2022-11-04T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1228627/000114036122040018/0001140361-22-040018-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1228627/000114036122040018/brhc10043741_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001140361-22-040018
- JSON: https://secwatch.observer/filing/0001140361-22-040018.json
- Plain text: https://secwatch.observer/filing/0001140361-22-040018.txt

## Key facts
- Earnings Releases
  Opus Genetics, Inc. reported financial results for quarter ended September 30, 2022.
  - Period: quarter ended September 30, 2022
  - Result: reported results
  source text: On November 4, 2022, Ocuphire Pharma, Inc. (the “Company”) issued a press release announcing its financial results for the quarter ended September 30, 2022.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1228627/000114036122040018/0001140361-22-040018-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.